Bio-Techne (TECH) investor relations material

Executive summary

• A merger agreement was entered into for Bio-Techne to become a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany, with a shareholder vote scheduled for September 23, 2026.

• Supplemental proxy disclosures were issued in response to shareholder litigation and demand letters alleging deficiencies in the original proxy statement.

• Forward-looking statements highlight risks related to the merger, including integration challenges, regulatory approvals, and potential business disruptions.

Voting matters and shareholder proposals

• Shareholders are being asked to vote on the proposed merger at a special meeting.

• Litigation seeks to enjoin the shareholder vote, alleging material omissions or misrepresentations in the proxy statement.

Board of directors and corporate governance

• The board delegated approval of Goldman Sachs' engagement terms to the Audit Committee, which authorized the engagement.

• Information about directors and executive officers, including compensation and governance, is referenced in prior proxy filings and SEC reports.